Ganoderic acid K
Ganoderic acid K is a triterpenoid compound. Ganoderic acid K can be isolated from Ganoderma lucidum. Ganoderic acid K inhibits ACE activity with an IC50 of 2.6×10-5 M. Ganoderic acid K exhibits direct, high-affinity binding to recombinant MD2 protein, with a Kd value of 0.47 μM. It potently inhibits LPS-induced release of TNF-α and IL-6. It reduces cerebral infarction volume and ameliorates neurological dysfunction in mice with ischemic stroke in the tMCAO model. Ganoderic acid K can be used in studies related to hypertension and ischemic stroke.
For research use only. We do not sell to patients.
- CAS No.: 104700-95-0
- Formula: C32H46O9
- Molecular Weight:574.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-6 |
Ganoderic acid K inhibits the activity of purified porcine kidney angiotensin-converting enzyme, with an IC50 value of 2.6×10-5 M[1].
Ganoderic acid K (25 μM; 1 h pretreatment) potently inhibits LPS-induced release of TNF-α and IL-6 in BV-2 mouse microglia, with inhibition rates of over 50% for both cytokines[2].
Ganoderic acid K (0.19-50 μM) exhibits direct, high-affinity binding to recombinant MD2 protein, with a Kd value of 0.47 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BV-2 murine microglial cells
-
Concentration:12.5, 25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Showed no cytotoxicity to BV-2 cells at all tested concentrations.
-
Cell Line:LPS-stimulated BV-2 murine microglial cells
-
Concentration:25 μM (pretreatment); 10 ng/mL LPS
-
Incubation Time:1 h (pretreatment); 12 h (LPS incubation)
-
Result:Significantly inhibited LPS-induced TNF-α and IL-6 release by more than 50% each.
Demonstrated the most pronounced inhibitory effect among the eight tested ganoderic acid monomers.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (8-week-old male, 23 g)[2]
-
Dosage:20 mg/kg
-
Administration:Not specified
-
Result:Significantly reduced cerebral infarct volume compared to vehicle-treated tMCAO mice.
Exhibited significantly lower neurological deficit scores relative to vehicle-treated tMCAO controls.
Chemical Information
-
CAS No. 104700-95-0
-
Molecular Weight 574.70
-
Formula C32H46O9
-
SMILES
C[C@@H]([C@H]1CC([C@]2(C)[C@]1(C)[C@H](OC(C)=O)C(C3=C2[C@@H](O)CC4[C@]3(C)CC[C@H](O)C4(C)C)=O)=O)CC(C[C@H](C(O)=O)C)=O
-
Initial Source
Ganoderma lucidum
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Morigiwa A, et al. Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum. Chem Pharm Bull (Tokyo). 1986 Jul;34(7):3025-8. [Content Brief]
[2]. Ma A, et al. Ganoderic Acids Alleviate Neuroinflammation by Targeting Myeloid Differentiation Factor 2 for Ischemic Stroke Therapy. Exploration (Beijing). 2026;6(1):20240147. Published 2026 Feb 18. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz